Ep300 (Ser89) Polyclonal Antibody, Cy5.5 Conjugated

Imprimir

Referência bs-5341R-Cy5.5

Tamanho : 100ul

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Marca : Bioss

Contactar o distribuidor local :

Telefone : +1 850 650 7790

bs-5341R-Cy5.5 [Conjugated Primary Antibody]

Ep300 (Ser89) Polyclonal Antibody, Cy5.5 Conjugated

www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]

DATASHEET

Host: Rabbit

Target Protein: Ep300 Ser89

Modification Site: Ser89

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 2033

Source: KLH conjugated synthetic phosphopeptide derived from human Ep300 around the phosphorylation site of Ser89

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

KAT3B/p300 is a transcriptional adapter protein (300 kDa)which is characterized by three cysteine and histidine rich regions and its C-terminus specifically binds the adenovirus E1A protein. KAT3B and associated proteins are components of TATA-binding protein (TBP)complexes. Protein kinase A mediated CREB phosphorylation results in the binding of CREB to a 265 kDa nuclear protein designated KAT3A/CBP(for CREB-binding protein). KAT3B and KAT3A are homologous to each other.

Conjugation: Cy5.5

Excitation/ Emission: 675nm/694nm

Size: 100ul

Concentration: 1ug/ul

Applications: IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 266

Predicted Cross Reactive Species: Human
Mouse
Rat
Dog
Cow
Sheep
Pig
Horse
Rabbit
Guinea Pig

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS

Hu Y et al. Ultrasensitive electrochemiluminescence immunosensor for the transcriptional co-activator p300 by using a graphene oxide monolayer and tetrahedral DNA-mediated signal amplification. Mikrochim Acta. 2019 May 2;186(5):325.Read more>>